Publications

Poster Presentation Approval / Commercialization Care Hepatology

Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry.

Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry

Approval / Commercialization Care Poster Presentation Hepatology

Real-World Treatment Patterns Among US Adults with Enresectable Hepatocellular Carcinoma (HCC) Eligible For Locoregional Therapy (LRT).

Real-World Treatment Patterns Among US Adults with Unresectable Hepatocellular Carcinoma (HCC) Eligible For Locoregional Therapy (LRT)

Abstract / Manuscript R&D Care Hepatology

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH.

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH

Abstract / Manuscript R&D Care Hepatology

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease.

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

Abstract / Manuscript R&D Care Hepatology

DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.

DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy

Total Publications

Abstract / Manuscript

Oral Presentation

Poster Presentation

2025 · Poster Presentation · Poster Presentation · Hepatology

Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry.

2025 · Poster Presentation · Approval / Commercialization · Hepatology

Real-World Treatment Patterns Among US Adults with Enresectable Hepatocellular Carcinoma (HCC) Eligible For Locoregional Therapy (LRT).

2025 · Abstract / Manuscript · Abstract / Manuscript

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH.

2025 · Abstract / Manuscript · Abstract / Manuscript

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease.

2025 · Abstract / Manuscript · Abstract / Manuscript

DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.

2025 · Poster Presentation · Poster Presentation · Hepatology

Changes in The Fibrosis-4 (FIB-4) Score Accurately Reflects The Disease Trajectory of Metabolic Dysfunction Associated Steatotic Liver Disease.

2025 · Poster Presentation · Poster Presentation · Hepatology

Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort.

2025 · Poster Presentation · Poster Presentation · Hepatology